No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Specialties
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
www.jafroninternational.comNo one on the platform currently holds 300529.SZ.
No tracked institution reports a position in 300529.SZ as of their last filing.
No one on the platform has traded 300529.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 25.5% | 35.7% | 47.2% | — | — | — |
| Rev. Growth % | -24.9% | 0.6% | ||||
| Profit Margin % | 26.5% | 32.1% | 36.1% | |||
| Free Cash Flow Margin % | 27.3% | 27.1% | 25.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | +0.8% | $0.81 | $0.81–$0.82 | — | 2 |
| 2027 | $2.3B | +7.6% | $0.89 | $0.88–$0.90 | — | 2 |
| 2028 | $2.5B | +8.0% | $0.99 | $0.99–$1.00 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-10-29 | $0.34 | $0.08 | -75.6% |
| 2025-08-21 | $0.18 | $0.26 | +44.4% |
| 2025-04-15 | $0.18 | $0.04 | -80.0% |
| 2025-04-15 | $0.18 | $0.23 | +27.8% |
| 2024-10-18 | $0.34 | $0.30 | -10.5% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300529.SZJafron Biomedical Co.,Ltd. | $14.98 | +0.54% | $12.0B | — |
| 000028.SZChina National Accord Medicines Corporation Ltd. | $19.72 | -0.25% | $10.5B | — |
| 000403.SZPacific Shuanglin Bio-pharmacy Co., Ltd. | $9.91 | -0.90% | $9.4B | — |
| 002019.SZYifan Pharmaceutical Co., Ltd. | $9.25 | +0.33% | $11.3B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. |
| $11.37 |
| -0.18% |
| $9.8B |
| — |
| 300595.SZAutek China Inc. | $9.94 | +0.00% | $8.9B | — |
| 301015.SZQingdao Baheal Medical Inc. | $23.22 | +1.31% | $12.2B | — |
Source: Financial Modeling Prep · peers by sector/industry